Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT03382912

Public ClinicalTrials.gov record NCT03382912. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.

Study identification

NCT ID
NCT03382912
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
52 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 21, 2018
Primary completion
Aug 27, 2019
Completion
Mar 2, 2020
Last update posted
Sep 10, 2020

2018 – 2020

United States locations

U.S. sites
35
U.S. states
16
U.S. cities
33
Facility City State ZIP Site status
Arizona Oncology Associates, P.C. Tempe Arizona 85284
Beverly Hills Cancer Center Beverly Hills California 90211
Glendale Adventist Medical Center Los Angeles California 90017
Redwood Regional Oncology Center Santa Rosa California 95403
The Oncology Institute of Hope and Innovation Whittier California 90602
Rocky Mountain Cancer Center Lone Tree Colorado 80124
John B. Amos Cancer Center Columbus Georgia 31904
Covenant Clinic Waterloo Iowa 50702
Baptist Health Medical Group Lexington Kentucky 40503
MedStar Health Research Institute Baltimore Maryland 21237
Maryland Oncology Hematology, P.A. Columbia Maryland 21044
Frederick Memorial Hospital Frederick Maryland 21701
Sparrow Health System Lansing Michigan 48912
Hattiesburg Clinic Hattiesburg Mississippi 39401
The Valley Hospital - Luckow Pavilion Westwood New Jersey 07675
Broome Oncology LLC Johnson City New York 13790
Winthrop University Hospital Mineola New York 11501
Clinical Research Alliance, Inc. New Hyde Park New York 11042
Stony Brook University Medical Center Stony Brook New York 11794
Gabrail Cancer Center Canton Ohio 44718
Christ Hospital Cincinnati Ohio 45219
University of Toledo Medical Center Toledo Ohio 43614-2598
Charleston Hematology Oncology Associates Charleston South Carolina 29414
Mamie McFaddin Ward Cancer Center Beaumont Texas 77702
Texas Oncology - Dallas Presbyterian Hospital Dallas Texas 75231
Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas Texas 75246
Texas Oncology-Memorial City Houston Texas 77024
Millennium Oncology Houston Texas 77090
Joe Arrington Cancer Center Lubbock Texas 79410
Texas Oncology - Midland Allison Cancer Center Midland Texas 79701
US Oncology The Woodlands Texas 77380
Texas Oncology - Tyler Tyler Texas 75702
Fairfax Northern Virginia Hematology Oncology, PC Fairfax Virginia 22031
Oncology and Hematology Associates of Southwest Virginia Inc Roanoke Virginia 24014
MultiCare Regional Cancer Center - Auburn Tacoma Washington 98002

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03382912, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 10, 2020 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03382912 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →